Abstract: Systems and approaches for manufacturing containers for cosmetic substances include providing a container body having a first end and a second end and defining a container cavity that receives a cosmetic substance, and, during a two-shot molding process, forming 1) a container neck having a first end, a second end, and a neck wall and defining a neck cavity; and 2) a wiper integrally formed with at least a portion of the neck wall. The wiper includes a protrusion extending into the neck cavity. The container neck is operably coupled with the first end of the container body.

Abstract: Embodiments of this application disclose a collective communication method, apparatus, and system. The method includes: A first network device receives a first packet; the first network device receives at least one second packet; and the first network device sends a third packet based on the first packet and the at least one second packet. When no connection is established between the first network device and a terminal device, the first network device may aggregate and distribute collective communication packets by using a connection between the first terminal device and another terminal device.

Abstract: A first communication apparatus obtains a sampling cycle. The sampling cycle is a time interval at which the first communication apparatus samples occupancy of a first buffer. The first buffer is used to store a data packet of a first priority. The first communication apparatus determines occupancy of the first buffer at a first sampling moment based on the sampling cycle. The first communication apparatus determines first duration based on the sampling cycle and the occupancy of the first buffer at the first sampling moment. The first duration is duration for which a second communication apparatus stops sending data to the first communication apparatus. The first communication apparatus sends first indication information to the second communication apparatus based on the first duration.

Abstract: Approaches for manufacturing an applicator and corresponding applicators for applying a cosmetic substance are provided that may include forming an applicator body, an applicator head, and a detachable shield. The applicator body includes a first end and a second end. The applicator head is operably coupled with the first end of the applicator body and includes an outer surface. The detachable shield being removably coupled with the applicator head. The outer surface of the applicator head is segmented into an exposed portion outside of the detachable shield and a shielded portion within the detachable shield. The approach further includes applying a surface treatment to the outer surface of the applicator head and removing the detachable shield from the applicator head. Upon removing the detachable shield, the shielded portion is free of the surface treatment.

Abstract: This application provides a collective communication method and a communication apparatus. The method includes: A first terminal device receives at least one second packet from a first network device, where the second packet includes information about a first process and information about a network device corresponding to the first process, the first process is used to execute a first task, and the information about the network device corresponding to the first process is information about a network device to which a terminal device including the first process belongs. The first terminal device determines a third packet based on the at least one second packet, where the third packet includes information about a target network device and information about all first processes that correspond to the target network device and that execute the first task.

Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof.

Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.

Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.

Abstract: Embodiments of this application disclose a collective communication method, apparatus, and system. The method includes: A first network device receives a first packet; the first network device receives at least one second packet; and the first network device sends a third packet based on the first packet and the at least one second packet. When no connection is established between the first network device and a terminal device, the first network device may aggregate and distribute collective communication packets by using a connection between the first terminal device and another terminal device.

Abstract: A dispensing pump mechanism is provided. The pump comprises integrally molded temper-evidence part between a container collar and a spout; said collar has multiple off-centre outlet channel for dispensing one or more products from the container; said collar also comprises an integrated air vent to be blocked and opened by the rotation of the spout. The whole pump can be over-molded one-piece structure with elastic parts as being actuating parts. The pump improves the functions of the pump, such as lower restitution rate, less structural parts, lower cost, water/dust proof, lightweight, easy assembly.

Abstract: A refillable dispenser for a stick product comprises a holder cup, an A-shell and an inner base. Preferably, the dispenser will also comprise an outer base and a closure. The holder cup and A-shell form a cartridge subassembly for a stick product that can be bottom filled, and removed and replaced as needed. The dispenser requires no lubricant.

Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.

Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.

Abstract: The use of anti-HPV immunogens and nucleic acid molecules that encode them for the treatment and prevention of vulvar dysplasia are disclosed. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response to treat or prevent vulvar dysplasia are disclosed.

Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

Abstract: The use of anti-HPV immunogens and nucleic acid molecules that encode them for the treatment and prevention of anal high-grade squamous intraepithelial lesion are disclosed. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent anal high-grade squamous intraepithelial lesion.

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof.